The ABSORB EXTEND study: Preliminary report of the twelvemonth clinical outcomes in the first 512 patients enrolled

EuroIntervention

Volumn 10, Issue 12, 2015, Pages 1396-1401

  Abizaid, Alexandre ^a   Costa, J Ribamar ^a   Bartorelli, Antonio L ^b   Whitbourn, Robert ^c   Van Geuns, Robert Jan ^d   Chevalier, Bernard ^e   Patel, Tejas ^f   Seth, Ashok ^g   Stuteville, Marrianne ^h   Dorange, Cécile ^h   Cheong, Wai Fung ^h   Sudhir, Krishnankutty ^h   Serruys, Patrick W ^d  

^a Instituto de Cardiologia Dante Pazzanese   (Brazil)

^b UNIVERSITY OF MILAN   (Italy)

^c ST VINCENT S HOSPITAL   (Australia)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^f Krishna Heart Institute   (India)

^g ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^h ABBOTT VASCULAR   (United States)

Author keywords

Bioresorbable scaffold; Coronary artery disease; Everolimus; Percutaneous coronary intervention; Poly (L lactide)

Indexed keywords

EVEROLIMUS; ANTINEOPLASTIC AGENT; CREATINE KINASE MB;

ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; SAFETY; AGED; BIODEGRADABLE IMPLANT; COHORT ANALYSIS; CORONARY ARTERY THROMBOSIS; CORONARY STENOSIS; DRUG ELUTING STENT; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; TISSUE SCAFFOLD; TREATMENT OUTCOME; CARDIOVASCULAR PARAMETERS; EQUIPMENT DESIGN; GEOGRAPHIC DISTRIBUTION; MAJOR ADVERSE CARDIAC EVENT; OPEN STUDY; POPULATION RESEARCH; STENT THROMBOSIS;

ABSORBABLE IMPLANTS; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84928396540     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I12A243     Document Type: Article

References (14)

1. Ormiston JA, De Vroey F, Serruys PW, Webster MW Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. 2011; 4:535-8.
2. Sarno G, Bruining N, Onuma Y., Garg S, Brugaletta S, De Winter S, Regar E, Thuesen L., Dudek D, Veldhof S, Dorange C., Garcia-Garcia HM, Ormiston JA, Serruys PW Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging. 2012; 28:51-8.
3. Ormiston JA, Serruys PW, Regar E, Dudek D., Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371:899-907.
4. Serruys PW, Onuma Y, Ormiston J.A., de Bruyne B, Regar E, Dudek D., Thuesen L, Smits PC, Chevalier B, McClean D., Koolen J, Windecker S, Whitbourn R., Meredith I, Dorange C, Veldhof S., Mquel-Hebert K, Rapoza R, García-García HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010; 122:2301-12.
5. Oberhauser JP, Hossainy S, Rapoza R. Design principles and performance of bioresorbable polymeric vascular scaffolds. Euro Intervention. 2009; 5:F15-22.
6. Okamura T, Garg S, Gutierrez-Chico JL, Shin E.S., Onuma Y., Garcia-Garcia HM, Rapoza RJ, Sudhir K, Regar E., Serruys PW. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. Euro Intervention. 2010; 5:932-8.
7. Cutlip D, Windecker S, Mehran R., Boam A, Cohen D, van Es GA, Steg P, Morel MA, Mauri L, Vranckx P., McFadden E, Lansky A, Hamon M., Krucoff M, Serruys P; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344-51.
8. Ishibashi Y, Onuma Y, Muramatsu T., Nakatani S, Iqbal J, Garcia-Garcia HM, Bartorelli A.L., Whitbourn R., Abizaid A, Serruys PW. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. Euro Intervention. 2014; 10:449-57.
9. Dudek D, Onuma Y, Ormiston J.A., Thuesen L., Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Euro Intervention. 2012; 7:1060-1.
10. Serruys PW, Ormiston JA, Onuma Y, Regar E., Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N., Dorange C, Mquel-Hebert K, Veldhof S, Webster M., Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373:897-910.
11. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L., Smits PC, Chevalier B, McClean D, Koolen J., Windecker S, Whitbourn R, Meredith I., Dorange C, Veldhof S, Hebert K.M., Rapoza R., Garcia-Garcia HM. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multiimaging modality study. Circ Cardiovasc Interv. 2012; 5:620-32.
12. Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys PW. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. Euro Intervention. 2007; 3:315-20.
13. Stone GW, Mdei M, Newman W., Sanz M, Hermiller JB, Williams J, Farhat N., Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X., Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008; 299: 1903-13.
14. Meredith IT, Worthley S, Whitbourn R., Walters DL, McClean D, Horrigan M, Popma J.J., Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ; RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009; 2:977-85.